Savara Inc Increase (Decrease) in Income Taxes Receivable
Savara Inc (SVRA) reported Increase (Decrease) in Income Taxes Receivable of $1.39 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2018-11-07
- Savara Inc increase (decrease) in income taxes receivable for the quarter ending 2018-09-30 was $156.00K, a 31.09% increase year-over-year.
- Savara Inc increase (decrease) in income taxes receivable for the quarter ending 2018-06-30 was $364.00K, a 27.35% decline year-over-year.
- Savara Inc increase (decrease) in income taxes receivable for the quarter ending 2018-03-31 was $873.00K, a 429.09% increase year-over-year.
- Savara Inc increase (decrease) in income taxes receivable for the quarter ending 2017-12-31 was -$331.00K.
- Savara Inc increase (decrease) in income taxes receivable for fiscal 2017 was $454.00K.
- Savara Inc increase (decrease) in income taxes receivable for fiscal 2016 was -$393.00K.
| Period end | Increase (Decrease) in Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Receivable 9 month | Increase (Decrease) in Income Taxes Receivable 12 month |
|---|---|---|---|---|
| 2018-09-30 | $156.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $520.00K derived: sum of 2 quarters · filed 2018-11-07 | $1.39M 10-Q · filed 2018-11-07 | $1.06M derived: sum of 4 quarters · filed 2018-11-07 |
| 2018-06-30 | $364.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $1.24M 10-Q · filed 2018-08-09 | $906.00K derived: sum of 3 quarters · filed 2018-08-09 | $1.02M derived: sum of 4 quarters · filed 2018-11-07 |
| 2018-03-31 | $873.00K 10-Q · filed 2018-05-09 | $542.00K derived: sum of 2 quarters · filed 2018-05-09 | $661.00K derived: sum of 3 quarters · filed 2018-11-07 | $1.16M derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-12-31 | -$331.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$212.00K derived: sum of 2 quarters · filed 2018-11-07 | $289.00K derived: sum of 3 quarters · filed 2018-11-07 | $454.00K 10-K · filed 2018-03-14 |
| 2017-09-30 | $119.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $620.00K derived: sum of 2 quarters · filed 2018-11-07 | $785.00K 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $501.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $666.00K 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $165.00K 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | -$393.00K 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |